NCT01589159View on ClinicalTrials.gov

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2016

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Capecitabine

Drug:capecitabine 700mg/m2, twice daily on days 1-14.

DRUG

Etoposide

Etoposide 30mg/m2, once daily on days 1-7.

Trial Locations (1)

100142

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Tao OUYANG

OTHER

NCT01589159 - A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes | Biotech Hunter | Biotech Hunter